Investor Information
Financial Overview
At November 30, 2020, the following common share purchase options were outstanding:
Share purchase options
At November 30, 2020 the following common share purchase options were outstanding:
| Expiry Date |
Number Outstanding |
Exercise Price |
Vested (Exercisable) |
| May 4, 2021 |
630,000 |
0.05 |
630,000 |
| June 28, 2021 |
75,000 |
0.10 |
75,000 |
| January 9, 2022 |
2,250,000 |
0.17 |
2,250,000 |
| February 26, 2023 |
2,100,000 |
0.15 |
2,100,000 |
| September 24, 2024 |
1,530,000 |
0.07 |
1,020,000 |
| October 5, 2025 |
4,000,000 |
0.12 |
4,000,000 |
| November 4, 2025 |
500,000 |
0.175 |
166,666 |
| November 17, 2025 |
650,000 |
0.20 |
650,000 |
| |
11,085,000
|
|
10,241,666
|
Share purchase warrants
At November 30, 2020 there were no share purchase warrants outstanding.
Financial Statements
| Fiscal Year 2020 |
| 3rd Quarter Report for the period ended September 30, 2020 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2020 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2020 |
FS |
MD&A |
| Fiscal Year 2019 |
| Audited Annual Financial Statements for the year ended December 31, 2019 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2019 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2019 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2019 |
FS |
MD&A |
| Fiscal Year 2018 |
| Audited Annual Financial Statements for the year ended December 31, 2018 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2018 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2018 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2018 |
FS |
MD&A |
| Fiscal Year 2017 |
| Audited Annual Financial Statements for the year ended December 31, 2017 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2017 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2017 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2017 |
FS |
MD&A |
| Fiscal Year 2016 |
| Audited Annual Financial Statements for the year ended December 31, 2016 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2016 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2016 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2016 |
FS |
MD&A |
| Fiscal Year 2015 |
| Audited Annual Financial Statements for the year ended December 31, 2015 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2015 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2015 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2015 |
FS |
MD&A |
| Fiscal Year 2014 |
| Audited Annual Financial Statements for the year ended December 31, 2014 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2014 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2014 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2014 |
FS |
MD&A |
| Fiscal Year 2013 |
| Audited Annual Financial Statements for the year ended December 31, 2013 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2013 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2013 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2013 |
FS |
MD&A |
| Fiscal Year 2012 |
| Audited Annual Financial Statements for the year ended December 31, 2012 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2012 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2012 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2012 |
FS |
MD&A |
| Fiscal Year 2011 |
| Audited Annual Financial Statements for the year ended December 31, 2011 |
FS |
MD&A |
Contact Investor Information